ArticleLeukemia2018
Ninety-minute daratumumab infusion is safe in multiple myeloma.
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication.The oncologist · 2024Article
- Safety and feasibility analysis of rapid daratumumab infusion in Chinese patients with multiple myeloma.Cancer medicine · 2024Article
- Article
- [Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.Clinical pharmacokinetics · 2023Review
- Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.Blood cancer journal · 2023Article
- Anti CD38 monoclonal antibodies for multiple myeloma treatment.Human vaccines & immunotherapeutics · 2022Review
- Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.Therapeutic advances in hematology · 2022Review
- Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.Frontiers in oncology · 2022Article
- Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider.Journal of the advanced practitioner in oncology · 2021Review
- Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study.Drugs - real world outcomes · 2021Article
- Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).Haematologica · 2021Article
- Antibody-Based Treatment Approaches in Multiple Myeloma.Current hematologic malignancy reports · 2021Review
- Review
- [Progress in the treatment of multiple myeloma with daratumumab].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.ClinicoEconomics and outcomes research : CEOR · 2021Article
- Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.Therapeutic advances in hematology · 2021Review
- The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak.Oncotarget · 2020Article
- Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.British journal of haematology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.